Drug intelligence / Profile preview

SA02e

Development stage: Preclinical
Lead developer: Kensana Health
Modality: Small Molecules

Overview

SA02e is a preclinical-stage phytopharmaceutical candidate being developed by Kensana Health for the treatment of epilepsy. It is a cannabinoid-based therapeutic designed to leverage the anticonvulsant properties of cannabis-derived compounds to manage seizure activity. Kensana Health specializes in the development of standardized, pharmaceutical-grade cannabinoid medicines, aiming to provide consistent and effective treatments for neurological conditions. The drug is currently in the preclinical phase of development, focusing on establishing its efficacy and safety profile for seizure control.

Beyond the preview

Go deeper on SA02e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA02e.

Explore the full profile